Press release
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development
Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. Dr. Yuxin Chen, with a strong academic background and solid capabilities in converting academic research into industrial applications, successfully led the global R&D and clinical development of multiple first-in-class (FIC) innovative drugs. The core products of ProteLight Pharmaceuticals, founded by Dr. Chen, have entered pivotal clinical trials in both China and the United States. They demonstrate outstanding original R&D capabilities and a forward-looking international development strategy. Dr. Chen was named a 2025 Forbes China Pioneer Innovator in Industry Development.
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.,
[Honored as a 2025 Forbes China Pioneer Innovators in Industry Development]
Image: https://www.globalnewslines.com/uploads/2025/05/495282c2facd6379eb09fc3c07020f15.jpg
Dr. Wang Xin, Global Partner and President of Sullivan Greater China, together with Professor Yu Wang, Expert Advisor to the Judging Committee and Chairman of Chinese Foundation for Hepatitis Prevention and Control, presented the award to Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
China's Pioneer in Antimicrobial Peptide Innovation: ProteLight Pharma's Peceleganan Ushers in a New Era of Anti-Infective Therapy
ProteLight Pharma has achieved a historic breakthrough in China's innovative drug development with its independently developed antimicrobial peptide spray Peceleganan (PL-5). It is the first antimicrobial peptide innovative drug in China to enter clinical trials and submit a New Drug Application (NDA), and it has also advanced to Phase II clinical trials in the United States. In addition, it has been granted the WHO International Nonproprietary Name (INN) "Peceleganan," marking the first time a Chinese-developed antimicrobial peptide compound has obtained an international nonproprietary name. Dr. Yuxin Chen, founder of ProteLight Pharma, proposed the revolutionary "Membrane Discrimination Mechanism," which fundamentally addresses the problem of antimicrobial resistance. In clinical trials, the Peceleganan spray demonstrated broad-spectrum efficacy, high potency, and a low potential for resistance. This breakthrough innovation received the "Peptide Application Special Award" at the 15th Chinese International Peptide Symposium. Based on this original mechanism, ProteLight Pharma has established a world-leading rational design platform for antimicrobial peptide drug development, along with an advanced formulation R&D platform for peptide drugs, laying a solid foundation for the future growth of its product pipelines.
A Full Value Chain Creator: An Outstanding Model of R&D Breakthroughs and Commercialization
ProteLight Pharma has signed an exclusive cooperation agreement with China's pharmaceutical giant Chia Tai Tianqing, which is responsible for the full-scale commercialization of the PL-5 spray in the Chinese market. The company is now valued at over 2 billion RMB and has secured more than 60 million RMB in funding from the national "12th Five-Year Plan" and "13th Five-Year Plan" Major New Drug Innovation Programs, as well as from provincial and municipal science and technology funds. Notably, PL-5 has demonstrated significantly better clinical efficacy than traditional antibiotics in treating difficult-to-heal infected wounds such as diabetic foot ulcers and extensive burns. It has consistently met primary endpoints across all phases of clinical trials, providing a Chinese solution to the global problem of drug-resistant bacterial infections. In addition to anti-infective therapies, ProteLight Pharma is also expanding into oncology, autoimmune diseases, and metabolic disorders. The company has already developed several preclinical-stage innovative drug candidates in these areas.
China's Strength in the Global Battle Against Antimicrobial Resistant Bacteria: Building a Sustainable Biopharmaceutical Innovation Engine
Facing the growing global crisis of antibiotic resistance, ProteLight Pharma is seizing the historic opportunity for antimicrobial peptide drug development and has laid out a clear development plan. Peceleganan is expected to obtain its new drug certificate in early 2026, and the follow-up product PL-18 is scheduled to enter Phase III clinical trials in China in the fourth quarter of 2025. The company is currently advancing its Round E financing, with a focus on strengthening its R&D system and expanding its product pipeline. Dr. Yuxin Chen emphasized that ProteLight Pharma will remain committed to continuous innovation based on its original technology platform. Through further development and application of the "Membrane Discrimination Mechanism," the company aims to systematically address key technical challenges from drug discovery to industrialization. Committed to tackling global public health challenges, ProteLight Pharma strives to become a global leader in the field of antimicrobial peptides. This strategic positioning reflects the company's strong sense of social responsibility and highlights the ambition and strength of Chinese innovative pharmaceutical companies in global health governance.
About Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
Founded in April 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. is a high-tech biopharmaceutical company focused on the research, development, and production of peptide and small-molecule drugs. The company is based in Jiangyin Hi-Tech Industrial Development Zone, Jiangsu Province, and is recognized as a National High Tech Enterprise. ProteLight Pharma has several subsidiaries, including wholly owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as Jiangsu Putai Pharmaceutical Technology Co., Ltd., ProteLight Medical Holdings (Hong Kong) Co., Ltd., and ProteLight Pharma (Australia) Pty Ltd.
Innovation-driven drug R&D and production is the core strategy of the company. It has built a diversified pipeline of first-in-class peptide and small-molecule innovative drugs, with a focus on anti-infective, oncology, autoimmune, and metabolic diseases. The company holds dozens of patents, including PCT international patents, U.S. and EU patents, Chinese invention patents, utility model patents, and design patents.
Since its founding, ProteLight Pharma has undertaken over 40 scientific research projects, including the national "Major New Drug Innovation" projects under the 12th and 13th Five-Year Plans, and the "Funding Program for Preferential Returned Scientific Research Students Innovative and Start-ups."
The company was selected as one of the first key entrepreneurial teams by the Overseas Chinese Affairs Office and was awarded the "Outstanding Entrepreneur Award".
Looking ahead, the company will continue to build on its antimicrobial peptide product foundation, maintaining a balanced focus on R&D and business operations. With high-quality innovative products, ProteLight Pharma aims to become a global leader in the field of antimicrobial peptide pharmaceuticals.
About the 2025 Forbes China Pioneer Innovators in Industry Development Selection
The "2025 Forbes China Pioneer Innovators in Industry Development" selection is jointly organized by Forbes China and Frost & Sullivan. It aims to identify and recognize entrepreneurs who demonstrate innovation and leadership in key areas such as life sciences, industry and energy, AI and information technology, and consumer finance and services. The evaluation process adopts rigorous data analysis and case study methodologies to comprehensively assess candidates' innovation strategies, market influence, and growth potential. This selection not only serves as an authoritative recognition of industry leaders, but also aims to inspire more entrepreneurs to embrace technological innovation and contribute to the sustainable development of their industries.
Media Contact
Company Name: Frost & Sullivan
Contact Person: Qian Li
Email: Send Email [http://www.universalpressrelease.com/?pr=dr-yuxin-chen-president-and-ceo-of-jiangsu-protelight-pharmaceutical-biotechnology-co-ltd-honored-as-a-2025-forbes-china-pioneer-innovators-in-industry-development]
Country: China
Website: http://www.frostchina.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development here
News-ID: 4009178 • Views: …
More Releases from Getnews
Inspire Ambitions Unveils New Report Showing Graduate Expectation Gap in the UAE …
Inspire Ambitions launches "The 2025 Graduate Expectation Gap Report," highlighting disconnects between student career expectations and workplace realities.
Image: https://www.globalnewslines.com/uploads/2025/09/6f6df43eab6fb7f22996fcc669a39629.jpg
A new report released today by Inspire Ambitions [https://inspireambitions.com/], The 2025 Graduate Expectation Gap Report [https://inspireambitions.com/product/from-campus-to-career/], reveals that a significant majority of recent graduates in the UAE feel unprepared for the realities of today's workplace. The findings shed light on a widening divide between university preparation and the skills needed to succeed…
Future Electronics and Infineon to Host Free Webinar on Next-Generation Smart HM …
Image: https://www.globalnewslines.com/uploads/2025/09/1757697276.jpg
Future Electronics & Infineon's free webinar on Sept 25 to explore how PSOC Trademark Edge powers next-gen smart HMIs with AI, voice & gesture control.
Montreal, Canada - September 12, 2025 - Future Electronics, a leading global distributor of electronic components, is pleased to announce an upcoming free webinar hosted in collaboration with Infineon Technologies: Unlock Innovation with PSOC Trademark Edge for Next-Gen Smart HMIs.
The live session will take place…
RoadMap Advisors Enhances Sell-Side M&A Services for Middle Market Business Owne …
Image: https://www.globalnewslines.com/uploads/2025/09/1757662626.jpg
RoadMap Advisors, a Virginia-based consulting firm, has refined its sell-side M&A service offerings to provide greater process efficiency, buyer alignment, and transaction readiness for business owners seeking full or partial exits.
Vienna, VA - September 12, 2025 - RoadMap Advisors, a leading consulting firm in Tysons, VA [https://www.roadmapadvisors.com/], has announced the refinement of its sell-side mergers and acquisitions (M&A) services [https://www.roadmapadvisors.com/mergers-acquisitions/sell-side/], incorporating a structured, advisor-led process designed to help business…
MFE Insurance Responds to Industry Shift as Studios Turn to DICE Insurance for I …
Image: https://www.globalnewslines.com/uploads/2025/09/1757659532.jpg
MFE Insurance is offering custom DICE insurance policies for studios and filmmakers seeking to innovate their productions.
Los Angeles, CA - September 12, 2025 - As audience expectations continue to shift and demand for high-impact, visually memorable content rises, producers and production companies are pushing creative boundaries like never before. MFE Insurance, a national leader in entertainment, cannabis, and event insurance, [https://www.mfeinsurance.com/] is meeting that evolution head-on with customized DICE…
More Releases for ProteLight
Diabetic Foot Ulcers Pipeline: Leading Innovation with 20+ Groundbreaking Therap …
The Diabetic Foot Ulcers market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Cell2Cure ApS, Lakewood-Amedex, and FibroBiologics. These industry pioneers are transforming treatment strategies and redefining the future of Diabetic Foot Ulcers, bringing new hope to patients worldwide.
DelveInsight's "Diabetic Foot Ulcers Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Diabetic Foot Ulcers market. The report…
Mouth Odor Remover Market Future Growth, Top Leading Players, Revenue and Foreca …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Mouth Odor Remover market with holistic insights into vital factors and aspects that impact future market growth. The global Mouth Odor Remover market has been analyzed for the forecast period. In order to help players to gain a comprehensive understanding of the global Mouth Odor Remover market and its critical dynamics, the research study provides detailed qualitative and…
Breath Freshener Spray Market Strategic Insights Of Developing Industry Growing …
The latest research on Breath Freshener Spray Market provides a thorough examination of the most current developments in the Breath Freshener Spray and the key dynamics that are driving growth. It is a research report that examines market drivers, restraints, challenges, risks, and development prospects in the global market for Breath Freshener Spray. The global Breath Freshener Spray market report is a systematic study of the Breath Freshener Spray industry,…
Antimicrobial Peptides Market Growth, Competitive Analysis and Forecast 2027| An …
The global Antimicrobial Peptides market size is expected to reach US$ 6 million by the end of 2027, with a CAGR of 5.4% during 2021-2027. Antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which…
Animal Antimicrobial Peptides Market global outlook and forecast 2021 -2027
The Global Animal Antimicrobial Peptides Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Animal Antimicrobial Peptides makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise spins around the…
Plant Antimicrobial Peptides Market global outlook and forecast 2021 -2027| Prot …
The Global Plant Antimicrobial Peptides Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Plant Antimicrobial Peptides makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise spins around the…
